| Literature DB >> 34977369 |
Yuko Kondo1, Mami Kanzaki1,2, Daisuke Ishima1,2, Ryo Usui1,2, Ayato Kimura1,2, Kotaro Usui1,2, Yasuyuki Amoh3, Yasuo Takeuchi4, Toshihiro Kumabe5, Junya Ako6, Kagami Miyaji7, Kazutoshi Nishiyama1,2, Tsugio Akutsu1,2.
Abstract
BACKGROUND AND AIMS: Cholesterol crystal embolism-related cerebral infarction (CCE-CI) is frequently misdiagnosed due to the lack of specific symptoms. To aid in differential diagnosis, this study comprehensively characterized the magnetic resonance imaging (MRI) and clinical manifestations of CCE-CI and compared these features to those of atherothrombotic cerebral infarction (ACI).Entities:
Keywords: ACI, Atherothrombotic cerebral infarction; Atheroembolism; Atherothrombotic cerebral infarction; CAS, Carotid artery stenting; CCE, Cholesterol crystal embolism; CI, Confidence intervals; CRP, C-reactive protein; CTA, Computed tomography angiography; Cerebral infarction; Cholesterol crystal embolism; Cholesterol crystal embolism-related cerebral infarction; DWI, Diffusion-weighted imaging; Diffusion-weighted imaging; IRB, Institutional review board; LDL, Low-density lipoprotein; MRA, Magnetic resonance angiography; MRI, Magnetic resonance imaging; OR, Odds ratios; PCI, Percutaneous coronary intervention; TIA, Transient ischemic attack
Year: 2021 PMID: 34977369 PMCID: PMC8683713 DOI: 10.1016/j.ensci.2021.100388
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Clinical and laboratory features of CCE-related cerebral infarction.
| Patient No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 71 | 68 | 75 | 70 | 71 | 79 | 77 | 84 | 66 | 81 |
| Sex | M | M | M | M | M | M | F | M | M | F |
| Clinical presentation | ||||||||||
| Skin lesions | ||||||||||
| Toe petechiae and ischemia | + | NA | + | + | + | + | + | + | + | + |
| Livedo reticularis on the lower legs and feet | + | NA | + | + | + | − | + | − | − | + |
| Extracutaneous findings | ||||||||||
| Renal dysfunction | + | + | + | + | + | + | + | + | + | + |
| Retinal lesions | NA | − | − | − | + | NA | NA | NA | NA | NA |
| Conjunctival petechiae | NA | − | − | − | + | NA | NA | NA | NA | NA |
| Consciousness disturbance | − | + | − | − | − | − | + | − | − | − |
| Cognitive impairment | − | − | − | − | − | − | − | − | − | − |
| Hemiparesis | − | − | − | + | − | − | + | + | − | − |
| Hemodialysis | + | + | + | + | − | − | − | − | + | − |
| Laboratory findings | ||||||||||
| Urinalysis | normal | protein 2+, RBC 4/HPF, WBC <5/HPF, waxy casts 1+ | NA | NA | NA | protein 2+, RBC 2/HPF, WBC <5/HPF, hyaline casts 1+ | protein -, RBC >100/HPF, WBC <5/HPF | NA | protein 2+, RBC 4/HPF, WBC >100/HPF | NA |
| eGFR, mL/min/1.73m2 | 9.9 | 5.2 | 17.0 | 4.6 | 42.0 | 39.5 | 28.7 | 39.0 | 12.9 | 27.0 |
| Blood eosinophil count, cells/μL | 1800 | 1460 | 991 | 2151 | 482 | 441 | 25 | 35 | 110 | 638 |
| CRP, mg/dL | 0.31 | 10.95 | 2.36 | 0.47 | 0.24 | 0.17 | 1.90 | 0.87 | 1.47 | 0.49 |
| Precipitating factors | vascular surgery | − | CAG | − | CAS | anti-coagulation | CAG | PCI | − | PCI |
| Days to MRI after precipitating factors | 47 | − | 9 | − | 0 | 239 | 0 | 0 | − | 42 |
| Diagnostic procedures | autopsy | autopsy | skin biopsy | skin biopsy | skin biopsy | clinical | clinical | clinical | skin biopsy | skin biopsy |
| Comorbid conditions | ||||||||||
| Hypertension | + | + | + | + | + | + | + | + | + | + |
| Dyslipidemia | + | + | + | + | + | + | + | + | + | + |
| Diabetes mellitus | − | − | + | + | − | + | + | + | − | + |
| Coronary artery disease | − | − | + | − | + | − | + | + | − | + |
| Atrial fibrillation | − | − | − | − | − | − | − | − | − | + |
| Anticoagulant use | − | − | − | − | − | + | − | − | − | + |
| Antiplatelet drug use | − | + | + | − | + | − | + | + | − | − |
| Positive history of smoking | + | + | + | + | + | + | NA | NA | + | + |
| Malignancy | − | − | − | − | − | − | − | − | − | − |
| Neuroradiological findings | ||||||||||
| High-signal lesions on DWI | + | + | + | + | + | + | + | + | − | − |
| Supratentorial lesion on MRI | + | + | + | + | + | + | + | + | − | − |
| Infratentorial lesion on MRI | + | + | + | + | − | + | + | + | − | − |
| CTA performed | + | + | (MRA) | − | + | + | + | − | − | + |
| Plaque of ascending aorta and/or proximal arch | + | + | + | NA | + | + | + | NA | NA | + |
| Aortic aneurysm (TAA,AAA) | + | + | + | NA | − | + | + | NA | NA | − |
| CCA, ICA stenosis, or vulnerable plaque | − | − | − | NA | + | − | − | NA | NA | + |
Abbreviations: CCE, cholesterol crystal embolism; NA, not applicable; RBC, red blood cell; HPF, high-power field; WBC, white blood cell; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; CAG, coronary angiogram; CAS, carotid artery stenting; PCI, percutaneous coronary intervention; DWI, diffusion-weighted image; CTA, computed tomography; MRA, magnetic resonance angiography; TAA, thoracic aortic aneurysm; AAA, abdominal aortic aneurysm; CCA, common carotid artery; ICA, internal carotid artery.
Comparison of CCE-related CI and ACI clinicodemographic features.
| Variables | CCE-related CI | ACI | |
|---|---|---|---|
| (n = 6) | ( | ||
| Age, y (IQR) | 73 (71–76.5) | 73 (68.25–79.0) | 0.940 |
| >75 y, n (%) | 3 (50) | 50 (45.5) | 1.000 |
| Male sex, n (%) | 5 (83.3) | 91 (82.7) | 1.000 |
| Comorbid conditions, n (%) | |||
| Hypertension | 6 (100) | 94 (85.5) | 0.594 |
| Dyslipidemia | 6 (100) | 64 (58.2) | 0.080 |
| Diabetes mellitus | 3 (50) | 41 (37.3) | 0.672 |
| Coronary artery disease | 3 (50) | 21 (19.1) | 0.102 |
| Positive history of smoking | 5/5 (100) | 75/108 (69.4) | |
| Atrial fibrillation | 0 (0) | 6 (5.5) | 1.000 |
| Anticoagulant use | 1 (16.7) | 5 (4.5) | 0.278 |
| Antiplatelet drug use | 4 (66.7) | 37 (33.6) | 0.183 |
| Hemodialysis | 3 (50) | 0 (0) | <0.001*** |
| Laboratory and clinical data | |||
| eGFR, mL/min/1.73m2 | 22.9 (11.7–36.8) | 64.4 (51.8–76.9) | <0.001*** |
| Blood eosinophil count, cells/μL | 736.4 (451.0–1342.4) | 121.6 (57.9–196.1) | 0.006** |
| CRP > 1.0 mg/dL, n (%) | 3 (50) | 18 (16.4) | 0.072 |
| Consciousness disturbance | 2 (33.3) | 33 (30) | 1.000 |
| Hemiparesis | 1 (16.7) | 87 (79.1) | 0.003** |
| Malignancy | 0 (0) | 16 (14.5) | 0.594 |
| Neuroradiological findings | |||
| Plaque of ascending aorta and/or proximal arch | 6 (100) | 34 (30.9) | 0.001** |
| Aortic aneurysm (TAA, AAA) | 5 (83.3) | 13 (11.8) | <0.001*** |
| CCA, ICA stenosis, or vulnerable plaque | 1 (16.7) | 92 (83.6) | 0.001** |
| Supratentorial lesion on MRI | 6 (100) | 98 (89.1) | 1.000 |
| Infratentorial lesion on MRI | 5 (83.3) | 13 (11.8) | <0.001*** |
| 1 vascular territory DWI lesions | 0 (0) | 101 (91.8) | <0.001*** |
| 2 vascular territories DWI lesions | 3 (50) | 9 (8.2) | 0.014* |
| 3 vascular territories DWI lesions | 3 (50) | 0 (0) | <0.001*** |
Abbreviations: CCE, cholesterol crystal embolism; CI, cerebral infarction; ACI, atherosclerotic cerebral infarction; IQR, interquartile range; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; TAA, thoracic aortic aneurysm; AAA, abdominal aortic aneurysm; CCA, common carotid artery; ICA, internal carotid artery; DWI, diffusion-weighted imaging.
Fig. 1Representative axial diffusion-weighted magnetic resonance images from patients with CCE-CI showing infarcts in multiple vascular territories: Five patients (Nos. 2, 4, 6, 7, and 8 from Table 1) developed multiple infarcts in three territories (arrowhead), while three others (Nos. 1, 3, and 5 from Table 1) developed infarcts in two territories.
Fig. 2Distribution of DWI lesions: The vertical axis indicates the number of DWI lesions stratified by size for each patient.